Details for New Drug Application (NDA): 210855

NDA 210855 describes SODIUM NITROPRUSSIDE, which is a drug marketed by Abraxis Pharm, Amneal, Amphastar Pharms Inc, Avet Lifesciences, Baxter Hlthcare, Be Pharms, Caplin, Chartwell Rx, Cipla, Dr Reddys, Epic Pharma Llc, Eugia Pharma, Hainan Poly Pharm, Micro Labs, Mylan Labs Ltd, Nexus, Norvium Bioscience, Sagent Pharms Inc, Somerset Theraps Llc, Sun Pharm, Teva Parenteral, Xiromed, and Hainan Poly, and is included in twenty-three NDAs. It is available from fifteen suppliers. Additional details are available on the SODIUM NITROPRUSSIDE profile page.

The generic ingredient in SODIUM NITROPRUSSIDE is sodium nitroprusside. There are one thousand four hundred and seventy-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the sodium nitroprusside profile page.

Summary for 210855

Tradename:	SODIUM NITROPRUSSIDE
Applicant:	Cipla
Ingredient:	sodium nitroprusside
Patents:	0

Pharmacology for NDA: 210855

Physiological Effect

Vasodilation

Suppliers and Packaging for NDA: 210855

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
SODIUM NITROPRUSSIDE	sodium nitroprusside	INJECTABLE;INJECTION	210855	ANDA	Cipla USA Inc.	69097-532	69097-532-32	1 VIAL, SINGLE-DOSE in 1 CARTON (69097-532-32) / 2 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	INJECTABLE;INJECTION			Strength	25MG/ML
Approval Date:	Jul 16, 2018	TE:		RLD:	No

Complete Access Available with Subscription